Manuel E Engelhorn

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Autoimmunity and tumor immunity induced by immune responses to mutations in self
    Manuel E Engelhorn
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Med 12:198-206. 2006
  2. doi request reprint Mechanisms of immunization against cancer using chimeric antigens
    Manuel E Engelhorn
    The Swim Across America Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:773-81. 2008
  3. pmc Immune rejection of mouse tumors expressing mutated self
    Fei Duan
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:3545-53. 2009
  4. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
  5. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
  6. ncbi request reprint Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes
    Colin S B Houghton
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Vaccine 25:5330-42. 2007
  7. ncbi request reprint A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
  8. pmc Enhanced responses to tumor immunization following total body irradiation are time-dependent
    Adi Diab
    Swim Across America Laboratory of Tumor Immunology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e82496. 2013
  9. pmc Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
  10. pmc Antiviral T cell responses: phalanx or multipronged attack?
    David N Posnett
    Department of Medicine, Division of Hematology Oncology, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Exp Med 201:1881-4. 2005

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Autoimmunity and tumor immunity induced by immune responses to mutations in self
    Manuel E Engelhorn
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Med 12:198-206. 2006
    ..Thus, presentation of a vast repertoire of antigen variants to the immune system can enhance the generation of adaptive immune responses to self...
  2. doi request reprint Mechanisms of immunization against cancer using chimeric antigens
    Manuel E Engelhorn
    The Swim Across America Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:773-81. 2008
    ..Therefore large fusion vector panels such as those presented here can provide information to promote the successful advancement of gene-based vaccines...
  3. pmc Immune rejection of mouse tumors expressing mutated self
    Fei Duan
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:3545-53. 2009
    ..Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection...
  4. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
    ....
  5. ncbi request reprint DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  6. ncbi request reprint Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes
    Colin S B Houghton
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Vaccine 25:5330-42. 2007
    ..These data demonstrate that this approach can serve as the basis of epitope-engineering against cancer and intracellular pathogens...
  7. ncbi request reprint A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  8. pmc Enhanced responses to tumor immunization following total body irradiation are time-dependent
    Adi Diab
    Swim Across America Laboratory of Tumor Immunology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 8:e82496. 2013
    ..Clinical strategies using these approaches must therefore optimize such parameters, as the correct timing of infusion and vaccination may mean the difference between an ineffective treatment and successful tumor eradication. ..
  9. pmc Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
    ..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
  10. pmc Antiviral T cell responses: phalanx or multipronged attack?
    David N Posnett
    Department of Medicine, Division of Hematology Oncology, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Exp Med 201:1881-4. 2005
    ..Later, in the battle of Marathon described by Herodotus, the Greeks learned the advantages of multipronged attacks, a strategy still used in modern warfare. Is the immune system similar in its approach to combatting pathogens or tumors?..
  11. pmc Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
    ..These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor...
  12. ncbi request reprint Strategies to overcome immune ignorance and tolerance
    Miguel Angel Perales
    Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
    Semin Cancer Biol 12:63-71. 2002
    ..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed...